An analysis of Global Burden of Disease data from 1990 to 2023 shows pancreatic cancer prevalent cases reached 103,000 in China versus 66,000 in the United States in 2023, though China had lower age-standardized rates. High fasting plasma glucose surpassed tobacco as the leading attributable risk factor in the US, underscoring the rising role of metabolic risk. 

An international research team systematically reviews immune regulation, novel vaccines, biomarkers, and combination strategies with biologics.

Researchers at the Icahn School of Medicine at Mount Sinai have developed an artificial intelligence (AI) approach using data from wearable devices that can forecast upcoming periods of prolonged sitting in women with chronic pelvic pain disorders. The findings, published in the September 30 online issue of npj Women’s Health [DOI: 10.1038/s44294-026-00156-5], could inform personalized digital health tools that prompt the individual to move, such as by taking a short walk, at the right time while minimizing unnecessary alerts.

Researchers from the Faculty of Sport and Health Sciences at the University of Jyväskylä, Finland, found that biological ageing may accelerate already in early adulthood. In addition to lifestyle factors, environmental exposures and living environment may contribute to faster biological ageing. In the study, childhood and adolescent lifestyle and environmental exposures explained approximately 28% of the variation in biological age at the age of 22. 

October 6–7 | Abu Dhabi

Dr. Alex Aliper, Co-founder and President of Insilico Medicine, has been invited to speak at the AI Everything Abu Dhabi summit.

October 7–9 | Yokohama, Japan

Insilico Medicine will make an appearance at BioJapan 2026, held from October 7 to 9 at PACIFICO Yokohama, at Booth D74.

October 7–11 | San Francisco

Dr. Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine, has been invited to attend the Abundance Longevity Trip, founded by Dr. Peter Diamandis.

Nationwide Duke-NUS study finds asthma-related emergency visits rise within two days of increases in PM2.5, underscoring the importance of early precautions during periods of poorer air quality.

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), today announced the nomination of ISM1354, an AI-driven novel small molecule preclinical candidate (PCC) targeting GIPR, for the potential intervention of obesity, as well as obesity-related disorders including type 2 diabetes, with the potential to expand into cardiovascular diseases in regulating obesity-associated heart failure and more. Notably, in January of this year, Insilico announced the nomination of another GIPR antagonist, ISM0676, which demonstrated up to a 31.3% weight loss when used in combination with Semaglutide in humanized mouse models. In comparison, the newly nominated PCC maintains robust weight-loss efficacy while delivering further improvements in pharmacokinetic and safety profiles, while retaining its favorable drug-like properties.

Severe pneumococcal disease requiring hospitalization, most commonly pneumonia, can be a sign of previously undiagnosed blood cancer and immunodeficiency in adult patients, according to a study from the University of Gothenburg.